Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Acute Ischemic Stroke in Patients With Active Cancer

NCT07819526 · tracked via the Priya Life Science Japan tracker
Phase
Observational
Started
2026-03-01
Last updated
2026-09-21

Condition(s) studied

Acute Ischemic StrokeActive Cancer

Study summary

The goal of this multicenter prospective observational study, conducted at 24 hospitals in Japan, is to learn about recurrent ischemic stroke in people with active cancer who develop acute ischemic stroke. One of the main objectives is to evaluate how often ischemic stroke recurs during follow-up.

The main questions this study aims to answer are:

* How often does ischemic stroke recur within 3 months after the initial stroke?
* Which clinical factors may be associated with recurrent ischemic stroke?
* What other clinical outcomes occur during follow-up?

Participants will receive medical care determined by their treating physicians. Researchers will collect information about participants' cancer, stroke characteristics, test results, treatments, recurrent ischemic stroke, and other clinical outcomes. Researchers will also explore whether clinical factors are associated with recurrent ischemic stroke and other outcomes. This study will not assign participants to a specific treatment.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Acute ischemic stroke diagnosed within 7 days after symptom onset or the time last known well. 2. Active cancer at the time of the index stroke, as defined below. Exclusion Criteria: 1. The patient or a legally acceptable representative indicates that the patient does not wish to participate. 2. The investigator considers enrolment inappropriate.

Primary outcome measure(s)

  • Percentage of Participants With Recurrent Ischemic Stroke Within 3 Months — From enrollment through 3 months of follow-up
    The percentage of participants who experience recurrent ischemic stroke during follow-up. Recurrent ischemic stroke will be determined according to the criteria prespecified in the study protocol.

Trial sites (1)

FacilityCityRegionStatus
The Univeristy of Osaka Suita Osaka Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07819526 on ClinicalTrials.gov ↗ ← All trials in Japan